FDA Approves Durvalumab With Enfortumab Vedotin for MIBC
Summary
With the approval, there's a rival to perioperative pembrolizumab with enfortumab vedotin for patients with cisplatin-ineligible muscle-invasive bladder cancer.
Description from Medscape.
Who is covering this
-
FDA Approves Durvalumab With Enfortumab Vedotin for MIBC
With the approval, there's a rival to perioperative pembrolizumab with enfortumab vedotin for patients with cisplatin-ineligible muscle-invasive bladder cancer.






Comments
Comments need JavaScript.